Skip to content
NewsBlazeAU – Lifestyle
Author:
Telix Pharmaceuticals Limited
IPAX-2 Study of TLX101-Tx in First-line Glioblastoma Completes Enrolment and Confirms Dosing
May 18, 2026
New Publication Demonstrates TLX250-Px (Zircaix®) Potential in Diagnosing Kidney Cancers Beyond ccRCC
May 4, 2026
TLX101-Px (Pixlumi®) MAA Accepted in Europe
April 30, 2026
OPTIMAL-PSMA Trial of TLX597-Tx Next Generation RLT Presented at IPCS 2026 Highlighting Therapeutic Potential in Prostate Cancer
April 29, 2026
Educational Webinar: Unlocking the Potential of PSMA Therapy, A Next‑Generation Portfolio Approach
April 27, 2026
←
Previous Page
1
2
3